Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2004 May 17;14(10):2653-6.

Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 4.

Author information

1
Lilly Research Laboratories, A Division of Eli Lilly and Company, Indianapolis, IN 46285, USA.

Abstract

A series of 1-(1H-indol-4-yloxy)-3-(4-arylpiperidinyl)propan-2-ols possessing potent dual 5-HT(1A) receptor antagonism and serotonin reuptake inhibition was discovered. The fused aryl ring moiety contributed to the robust dual activities irrespective of the regiochemistry associated with its connectivity to the piperidine central ring.

PMID:
15109671
DOI:
10.1016/j.bmcl.2004.02.088
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center